MabtheraRituximab500 mgoneAmpouleRoche, Германия All Europe delivery. Shipping time 7-10 days. Price for shipping individual for each country. Usually 40-50 euro. Payment when sending the goods. \r\n Worldwide shipping possible too. \r\n Interchangeable drugs with the same active ingredient: \r\n \r\n Mabthera \r\n Reditux \r\n Rituxim \r\n Acellbia \r\n \r\n Indications. \r\n \r\n MabThera ® is indicated for adults in the following cases: \r\n non-Hodgkin\'s lymphoma \r\n Monotherapy of patients with stage III-IV follicular lymphoma who are resistant to chemotherapy or are in the stage of the second or subsequent relapses after chemotherapy. \r\n Treatment of CD20-positive diffuse large B-cell non-Hodgkin\'s lymphom...
All Europe delivery. Shipping time 7-10 days. Price for shipping individual for each country. Usually 40-50 euro. Payment when sending the goods.
Worldwide shipping possible too.
Interchangeable drugs with the same active ingredient:
Mabthera
Reditux
Rituxim
Acellbia
Indications.
MabThera®is indicated for adults in the following cases:
non-Hodgkin's lymphoma
Monotherapy of patients with stage III-IV follicular lymphoma who are resistant to chemotherapy or are in the stage of the second or subsequent relapses after chemotherapy.
Treatment of CD20-positive diffuse large B-cell non-Hodgkin's lymphoma in combination with CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine, prednisolone).
Treatment of previously untreated stage III-IV follicular lymphoma in combination with chemotherapy.
Maintenance therapy of follicular lymphomas after receiving a response to induction therapy.
chronic lymphocytic leukemia
Treatment of previously untreated and relapsed/refractory chronic lymphocytic leukemia in combination with chemotherapy.There are only limited data on efficacy and safety in patients previously treated with monoclonal antibodies, including MabThera®,or in patients refractory to previous treatment with MabTherapluschemotherapy.
rheumatoid arthritis
Treatment of severe rheumatoid arthritis (active form) in adults in combination with methotrexate when treatment with other disease-modifying antirheumatic drugs (FMDs) has failed or is intolerable, including treatment with one or more tumor necrosis factor inhibitors.
When used in combination with methotrexate, MabThera®reduces the rate of progression of destructive changes in the joints according to radiographic data and improves physical function.
Granulomatosis with polyangiitis and microscopic polyangiitis
Treatment of severe forms of active granulomatosis with polyangiitis (Wegener's granulomatosis) and microscopic polyangiitis in combination with corticosteroids to induce remission in adult patients
